December 1, 2014

homepage

October 1, 2020

Proteros Biostructures and X-Chem to offer Comprehensive Joint Target-to-Lead Drug Discovery Services

Munich, Germany and Waltham, Mass –October 1, 2020 – Proteros Biostructures GmbH (Proteros) and X-Chem, Inc. (X-Chem) announced today the launch of an alliance with the goal of offering Hit-Identification and Target-to-Lead drug discovery services based on their complementary technology platforms. The alliance combines Proteros’ strengths in protein sciences, structural biology (crystallography and CryoEM), and […]

Continue Reading
July 22, 2020

X-Chem Announces Achievement of Milestone In Orexia Collaboration

Waltham, Mass – July 22, 2020 – X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key development milestone in its collaboration with Orexia Limited (Orexia), a company focused on developing orexin positive modulators using unique structure based drug design capabilities.

Continue Reading
June 11, 2020

Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease

WALTHAM, Mass. – June 11, 2020 – X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process. The study, […]

Continue Reading